| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA1 Protein | 20 | 2023 | 200 | 2.160 |
Why?
|
| Genetic Predisposition to Disease | 34 | 2023 | 2271 | 2.030 |
Why?
|
| BRCA2 Protein | 16 | 2023 | 158 | 1.880 |
Why?
|
| Breast Neoplasms | 28 | 2023 | 2903 | 1.830 |
Why?
|
| Precision Medicine | 9 | 2021 | 395 | 1.680 |
Why?
|
| Ovarian Neoplasms | 15 | 2023 | 744 | 1.600 |
Why?
|
| Pharmacogenetics | 7 | 2024 | 434 | 1.430 |
Why?
|
| Genetic Testing | 8 | 2021 | 535 | 1.250 |
Why?
|
| Mutation | 24 | 2023 | 3968 | 1.140 |
Why?
|
| Genes, BRCA2 | 7 | 2019 | 160 | 1.050 |
Why?
|
| Genes, BRCA1 | 7 | 2019 | 192 | 1.040 |
Why?
|
| Primary Health Care | 3 | 2021 | 339 | 0.910 |
Why?
|
| Germ-Line Mutation | 8 | 2023 | 329 | 0.870 |
Why?
|
| Heterozygote | 16 | 2023 | 365 | 0.860 |
Why?
|
| Genetics, Population | 2 | 2021 | 394 | 0.780 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 57 | 0.760 |
Why?
|
| Genome-Wide Association Study | 12 | 2021 | 1621 | 0.750 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2022 | 2357 | 0.730 |
Why?
|
| Patients | 1 | 2021 | 100 | 0.730 |
Why?
|
| Health Literacy | 1 | 2021 | 70 | 0.710 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 1721 | 0.690 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 199 | 0.620 |
Why?
|
| Genomics | 5 | 2021 | 720 | 0.520 |
Why?
|
| Humans | 70 | 2024 | 86645 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2016 | 86 | 0.500 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 394 | 0.470 |
Why?
|
| Risk Factors | 21 | 2024 | 5417 | 0.460 |
Why?
|
| Female | 47 | 2023 | 44534 | 0.440 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 426 | 0.430 |
Why?
|
| Pharmacogenomic Testing | 3 | 2018 | 97 | 0.430 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 238 | 0.420 |
Why?
|
| Physicians | 2 | 2021 | 673 | 0.380 |
Why?
|
| Adult | 28 | 2024 | 25648 | 0.380 |
Why?
|
| Middle Aged | 25 | 2021 | 25028 | 0.380 |
Why?
|
| Risk Assessment | 9 | 2023 | 2262 | 0.370 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 39 | 0.360 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 71 | 0.360 |
Why?
|
| Alleles | 6 | 2021 | 1128 | 0.350 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 43 | 0.340 |
Why?
|
| Body Height | 2 | 2019 | 99 | 0.340 |
Why?
|
| Mastectomy | 3 | 2016 | 243 | 0.330 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 387 | 0.320 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 232 | 0.320 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.320 |
Why?
|
| Pedigree | 7 | 2020 | 966 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 166 | 0.310 |
Why?
|
| Quantitative Trait Loci | 6 | 2021 | 576 | 0.290 |
Why?
|
| Chromosome Mapping | 3 | 2020 | 1074 | 0.280 |
Why?
|
| Male | 25 | 2024 | 40967 | 0.270 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 456 | 0.270 |
Why?
|
| Body Mass Index | 2 | 2019 | 770 | 0.270 |
Why?
|
| Aged | 17 | 2024 | 18415 | 0.260 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 384 | 0.260 |
Why?
|
| Prostate | 2 | 2022 | 378 | 0.260 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1464 | 0.230 |
Why?
|
| Patient Transfer | 1 | 2014 | 91 | 0.230 |
Why?
|
| Community Health Planning | 3 | 2018 | 21 | 0.230 |
Why?
|
| Phenotype | 7 | 2023 | 2378 | 0.220 |
Why?
|
| Software | 2 | 2020 | 654 | 0.220 |
Why?
|
| DNA Copy Number Variations | 3 | 2022 | 171 | 0.220 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6509 | 0.220 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1805 | 0.210 |
Why?
|
| Exome | 3 | 2021 | 127 | 0.210 |
Why?
|
| Young Adult | 7 | 2021 | 5976 | 0.200 |
Why?
|
| Inpatients | 1 | 2014 | 297 | 0.200 |
Why?
|
| Health Personnel | 2 | 2021 | 202 | 0.200 |
Why?
|
| Intensive Care Units | 1 | 2014 | 374 | 0.200 |
Why?
|
| Heart Arrest | 1 | 2014 | 265 | 0.200 |
Why?
|
| Electronic Health Records | 1 | 2014 | 319 | 0.190 |
Why?
|
| Genetic Variation | 3 | 2019 | 1351 | 0.190 |
Why?
|
| Genotype | 7 | 2021 | 1851 | 0.190 |
Why?
|
| Mutation, Missense | 2 | 2020 | 276 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 153 | 0.190 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 19 | 0.190 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 57 | 0.190 |
Why?
|
| Patient Readmission | 1 | 2024 | 329 | 0.190 |
Why?
|
| Thrombosis | 1 | 2023 | 296 | 0.190 |
Why?
|
| Urinary Tract | 1 | 2020 | 34 | 0.180 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2262 | 0.180 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 112 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2023 | 4213 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 166 | 0.180 |
Why?
|
| Illinois | 1 | 2021 | 462 | 0.170 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Nipples | 2 | 2016 | 37 | 0.170 |
Why?
|
| Hexokinase | 1 | 2019 | 19 | 0.170 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 48 | 0.170 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 470 | 0.170 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 479 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2018 | 260 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 567 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2019 | 255 | 0.160 |
Why?
|
| Internationality | 1 | 2018 | 69 | 0.160 |
Why?
|
| Prognosis | 6 | 2019 | 3680 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 2501 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2024 | 8491 | 0.150 |
Why?
|
| Exons | 2 | 2016 | 450 | 0.150 |
Why?
|
| Transcriptome | 2 | 2020 | 580 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2020 | 403 | 0.150 |
Why?
|
| Genes, Modifier | 1 | 2017 | 5 | 0.150 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 294 | 0.150 |
Why?
|
| Community Pharmacy Services | 1 | 2016 | 5 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 1208 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 279 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.140 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 536 | 0.140 |
Why?
|
| Professional Role | 1 | 2016 | 41 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 59 | 0.140 |
Why?
|
| Genetic Carrier Screening | 1 | 2016 | 60 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2016 | 11 | 0.140 |
Why?
|
| Point Mutation | 2 | 2016 | 246 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 65 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 74 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 508 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 39 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 40 | 0.140 |
Why?
|
| Codon, Terminator | 1 | 2015 | 21 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 30 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2016 | 80 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.140 |
Why?
|
| Genes, Dominant | 1 | 2015 | 117 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 250 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 125 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2024 | 2767 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 859 | 0.130 |
Why?
|
| Connective Tissue Diseases | 1 | 2015 | 67 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 144 | 0.130 |
Why?
|
| Linkage Disequilibrium | 3 | 2021 | 473 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 938 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2014 | 81 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 280 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1373 | 0.120 |
Why?
|
| Mucin-1 | 1 | 2014 | 44 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 98 | 0.120 |
Why?
|
| Estrone | 1 | 2013 | 10 | 0.120 |
Why?
|
| G2 Phase | 1 | 2013 | 34 | 0.120 |
Why?
|
| Adolescent | 6 | 2020 | 8982 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 428 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 388 | 0.110 |
Why?
|
| Infant | 3 | 2020 | 3047 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 266 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 455 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2019 | 1538 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2020 | 1565 | 0.110 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 136 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2016 | 673 | 0.110 |
Why?
|
| Cell Division | 1 | 2013 | 696 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 353 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 1052 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 526 | 0.100 |
Why?
|
| United Kingdom | 2 | 2020 | 164 | 0.090 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 65 | 0.090 |
Why?
|
| Micrognathism | 1 | 2010 | 11 | 0.090 |
Why?
|
| Eye Abnormalities | 1 | 2010 | 41 | 0.090 |
Why?
|
| Karyotyping | 1 | 2010 | 250 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 361 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2010 | 229 | 0.090 |
Why?
|
| Gene Duplication | 1 | 2010 | 125 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 348 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1169 | 0.080 |
Why?
|
| Chicago | 1 | 2013 | 1379 | 0.080 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 195 | 0.080 |
Why?
|
| Family | 2 | 2020 | 311 | 0.080 |
Why?
|
| Gene Expression | 3 | 2016 | 1284 | 0.080 |
Why?
|
| Genome, Human | 1 | 2012 | 756 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2019 | 219 | 0.070 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 159 | 0.070 |
Why?
|
| Homozygote | 2 | 2023 | 200 | 0.070 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 674 | 0.060 |
Why?
|
| Protein Binding | 2 | 2020 | 1456 | 0.060 |
Why?
|
| Hospital Rapid Response Team | 1 | 2014 | 27 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2014 | 131 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 678 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1981 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2024 | 248 | 0.060 |
Why?
|
| Factor V | 1 | 2023 | 10 | 0.060 |
Why?
|
| Prothrombin | 1 | 2023 | 18 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 27 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1384 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 937 | 0.060 |
Why?
|
| Computational Biology | 2 | 2016 | 528 | 0.050 |
Why?
|
| Virulence | 1 | 2023 | 271 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 129 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 159 | 0.050 |
Why?
|
| Image-Guided Biopsy | 1 | 2022 | 66 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 853 | 0.050 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 2000 | 1 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 22 | 0.050 |
Why?
|
| Amphibian Proteins | 1 | 2020 | 3 | 0.050 |
Why?
|
| Biopsy | 2 | 2015 | 1163 | 0.050 |
Why?
|
| Calibration | 1 | 2020 | 99 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2014 | 575 | 0.050 |
Why?
|
| Morpholinos | 1 | 2020 | 13 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1197 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 1851 | 0.050 |
Why?
|
| Xenopus | 1 | 2020 | 125 | 0.050 |
Why?
|
| Glycine | 1 | 2020 | 92 | 0.050 |
Why?
|
| Larva | 1 | 2020 | 118 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2020 | 205 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2020 | 152 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1939 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 63 | 0.050 |
Why?
|
| Bronchi | 1 | 2020 | 229 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 2468 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 339 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 71 | 0.040 |
Why?
|
| Retinitis Pigmentosa | 1 | 2019 | 35 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 148 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 62 | 0.040 |
Why?
|
| Estrogens | 1 | 2020 | 200 | 0.040 |
Why?
|
| Mice | 3 | 2020 | 11352 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 261 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 677 | 0.040 |
Why?
|
| Child | 2 | 2020 | 6928 | 0.040 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 137 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 14 | 0.040 |
Why?
|
| Pregnancy-Specific beta 1-Glycoproteins | 1 | 2017 | 1 | 0.040 |
Why?
|
| Transcription Factors, TFII | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 8 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 223 | 0.040 |
Why?
|
| Disclosure | 1 | 2018 | 108 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 87 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3362 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2017 | 44 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 106 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 195 | 0.040 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 20 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 1577 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 85 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 408 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 129 | 0.030 |
Why?
|
| RNA Splice Sites | 1 | 2016 | 53 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 104 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 66 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1924 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 532 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2019 | 371 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 357 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 7993 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 147 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 351 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2016 | 142 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 95 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 609 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 288 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 201 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2016 | 623 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2705 | 0.030 |
Why?
|
| United States | 2 | 2024 | 6674 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 266 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 642 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 552 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3613 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 26582 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 103 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 554 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 636 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 2330 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 1187 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2062 | 0.030 |
Why?
|
| Data Collection | 1 | 2012 | 372 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3030 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 1106 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 1863 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 729 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 703 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 686 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1531 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1673 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 426 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 509 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1585 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 1241 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 621 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3640 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2426 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 5210 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2000 | 6 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2000 | 64 | 0.010 |
Why?
|
| Africa | 1 | 2000 | 98 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 110 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 145 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 162 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 819 | 0.010 |
Why?
|